Johan Drott
CEO
FIGHTING PROSTATE CANCER DIFFERENTLY
Science-driven development of diagnostics and therapeutics to specifically and efficiently treat prostate cancer. Diaprost is leading towards a different future.
Our mission
Diaprost´s research and development is targeting prostate cancer with ambition to revolutionize personalized medicine. The goal is to establish an antibody platform, for both in vivo diagnostic, to simplify and make the identification/detection of prostate cancer more reliable, as well as for targeted therapeutics.
Our background
Diaprost was founded in 2005 based on the idea that the transformative success of the PSA assay for detection of prostate cancer could be leveraged as a personalized theranostic platform. The technology and patent applications were pursued by leading researchers at Lund University.
Diaprost entered into an exclusive Research and Option Agreement. for the h11B6 project (targeting hK2), with a Top 10 pharmaceutical company as a strategic partner in October 2017.
In the beginning of 2020 Diaprost announced that its strategic partner has exercised its option to acquire the rights to its h11B6 antibody.
Diaprost is collaborating with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. Our scientists are active at some of the world´s most prominent centers in cancer research.
MANAGEMENT
Åke Fredriksson
Chairman of the Board
David Ulmert
Board member
Places
Lund University
Sweden
Turku University
Finland
Memorial Sloan Kettering
USA
Johns Hopkins Hospital
USA
Contact
ADDRESS
Diaprost AB
SE-223 81 Lund
VISITING ADDRESS
Medicon Village
Scheelevägen 2, Lund
CONTACT
+46 709 22 41 40
johan.drott@diaprost.com